A recent study, contrasting the present findings, has suggested that circLIFR is primarily located in the nucleus, interacting with MSH2 to modulate cisplatin sensitivity in bladder cancer via the MutSα/-p73 axis (Zhang et al. 2021a, b). Here, MSH2 is linked to urinary bladder carcinoma.